Phaeosynt produces vegan antibodies using a proprietary diatom-based bioprocess, offering an ethical and sustainable alternative to traditional animal-based methods for diagnostic assays. Their platform enables the generation of high-quality antibodies for diagnostic manufacturers seeking environmentally friendly solutions.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional antibody production for diagnostic applications often relies on animal-based methodologies, leading to ethical concerns and potential supply chain inconsistencies. The use of traditional plastics in diagnostic devices also presents environmental challenges.
Solution
Phaeosynt is developing a novel platform for producing vegan antibodies using diatoms, offering a sustainable and animal-free alternative for diagnostic assays. This proprietary bioprocess leverages genetically engineered diatoms to express antibodies, eliminating the need for animal suffering and animal-derived components. The company's initial product is a vegan pregnancy test, designed with bio-plastics to further enhance its environmental profile. Phaeosynt's approach aims to provide high-quality, ethically sourced antibodies for a range of diagnostic applications.
Target Audience
The primary target audience includes diagnostic assay developers and manufacturers seeking ethically sourced, sustainable antibody reagents and companies looking to produce vegan-certified diagnostic products.
Features
- Diatom-based antibody production platform for vegan and animal-free antibody generation.
- Proprietary bioprocess for expressing antibodies within genetically engineered diatoms.
- Use of bio-plastics in diagnostic device manufacturing for enhanced sustainability.
- Potential for producing antibodies of any class and origin.
- Focus on reducing the global reliance on animal-based antibody production.